GSK plc announced that on January 29, 2024, the European Commission authorized Omjjara (momelotinib) as the first medicine in the EU for treating splenomegaly and symptoms in adult myelofibrosis patients with moderate to severe anemia. This approval addresses the high unmet need as nearly all myelofibrosis patients are estimated to develop anemia during their illness.